SSSW(SH:688399)2022-04-27 16:00Financial Performance - The company's operating revenue for Q1 2022 reached ¥1,521,902,378.62, representing a year-on-year increase of 77.69%[3] - Net profit attributable to shareholders was ¥631,070,096.78, reflecting a growth of 62.90% compared to the same period last year[3] - Basic earnings per share increased to ¥10.77, up 62.93% year-on-year[3] - Operating profit for Q1 2022 was ¥744,064,455.92, up 62.2% from ¥458,996,646.78 in Q1 2021[16] - Net profit attributable to shareholders for Q1 2022 was ¥631,070,096.78, representing a 63.0% increase from ¥387,386,296.05 in Q1 2021[17] - Basic and diluted earnings per share for Q1 2022 were both ¥10.77, compared to ¥6.61 in Q1 2021[17] Cash Flow - The net cash flow from operating activities surged to ¥490,379,975.90, a significant increase of 1,930.58%[3] - Cash flow from operating activities for Q1 2022 was ¥490,379,975.90, a substantial increase from ¥24,149,786.61 in Q1 2021[20] - The company reported a net cash outflow from investing activities of ¥102,147,782.14 in Q1 2022, compared to a net outflow of ¥113,752,091.23 in Q1 2021[21] - The company experienced a net cash inflow from financing activities of ¥26,317,774.10 in Q1 2022, reversing a net outflow of ¥21,278,982.87 in Q1 2021[21] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥4,405,110,023.38, marking a 25.88% increase from the previous year[4] - The company's current assets totaled RMB 3,399,578,863.64, up from RMB 2,538,882,061.99, indicating a rise of about 33.9% year-over-year[11] - The total liabilities of the company amounted to RMB 1,237,590,025.15, compared to RMB 962,893,709.40, which is an increase of approximately 28.5%[13] - The company's equity attributable to shareholders reached RMB 3,167,519,998.23, up from RMB 2,536,449,901.45, representing a growth of about 25%[13] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 15,309[9] - The largest shareholder, Shaoxing RunKang Biological Pharmaceutical Equity Investment Partnership, held 26.61% of the shares, totaling 15,600,000 shares[9] Research and Development - Research and development expenses totaled ¥27,149,529.76, an increase of 65.07% year-on-year, accounting for 1.78% of operating revenue[3] - Research and development expenses for Q1 2022 were ¥27,149,529.76, up from ¥16,447,398.35 in Q1 2021, indicating a focus on innovation[16] Inventory and Receivables - Accounts receivable rose significantly to RMB 685,085,074.84, compared to RMB 342,578,380.56, marking an increase of about 100%[11] - Inventory levels increased to RMB 344,279,186.31 from RMB 250,346,454.01, indicating a rise of approximately 37.5%[12] Other Information - The company reported non-recurring gains of ¥6,311,173.46 for the period[6] - The company has not disclosed any new product or technology developments in this report[11] - There are no significant mergers or acquisitions reported during this period[11] - Total operating costs for Q1 2022 were ¥773,671,474.64, an increase of 93.6% from ¥399,799,615.17 in Q1 2021[16] - The company reported a significant increase in contract liabilities, which rose to RMB 184,179,624.49 from RMB 66,210,879.00, reflecting a growth of about 178%[12]